Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248787 | 1.00 | SIRT3 (0.45) | SIRT3TDP1CYP2A6CYP2E1CYP3A4 | |
| Hydrochloric Acid SCHEMBL15953194 | 0.98 | SIRT3 (0.44) | SIRT3TDP1CYP2A6CYP2E1CYP3A4 | |
| Hydrochloric Acid SCHEMBL29954682 | 0.98 | SIRT3 (0.44) | SIRT3TDP1CYP2A6CYP2E1CYP3A4 | |
| SCHEMBL23110401 | 0.85 | SIRT3 (0.41) | SIRT3TDP1CYP2A6CYP2E1CYP3A4 | |
| SCHEMBL708913 | 0.81 | SIRT3 (0.41) | SIRT3TDP1CYP2A6CYP2E1CYP3A4 | |
| SCHEMBL28204392 | 0.80 | SIRT3 (0.38) | SIRT3TDP1CYP2A6CYP2E1CYP3A4 | |
| Hydrochloric Acid SCHEMBL29958203 | 0.79 | SIRT3 (0.39) | SIRT3TDP1CYP2A6CYP2E1CYP3A4 | |
| Hydrochloric Acid SCHEMBL14797240 | 0.79 | SIRT3 (0.39) | SIRT3TDP1CYP2A6CYP2E1CYP3A4 | |
| SCHEMBL28376434 | 0.76 | KDM4E (0.38) | SIRT3TDP1NAPRT | |
| SCHEMBL361105 | 0.74 | GAA (0.46) | SIRT3TDP1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| EP-4402140-A1 | HETEROARYL-LINKED ANALOGS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | Vanderbilt University (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4402137-A1 | PHENYL CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | Vanderbilt University (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2024059220-A2 | 6,5 SOUTHWESTERN CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024059559-A1 | ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024059210-A2 | 6,5 WESTERN CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-4305040-A1 | TRICYCLIC PYRIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2024-01-17 | — | — | EP | disclosed |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2023043823-A1 | PHENYL CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023043833-A1 | HETEROARYL-LINKED ANALOGS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2023-03-23 | — | — | WO | disclosed |
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2023-01-12 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2022-09-29 | — | — | US | disclosed |
| WO-2022189387-A1 | TRICYCLIC PYRIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-3997096-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | SIRT3 3108/4885TDP1 2107/4885CYP2A6 4016/4885 |
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP4K2, MAP4K4 | SIRT3 1703/4885TDP1 981/4885CYP2A6 1988/4885 |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | SIRT3 1818/4885TDP1 1923/4885CYP2A6 624/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | SIRT3 1818/4885TDP1 1923/4885CYP2A6 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.